The peptide problem: Hype is outrunning the evidence FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and Female Fertility: Effects, Mechanisms, Safety and Risks